Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 
and Its Derivatives in a Goat Model

Figl, J.; Köhler, H.; Wedlich, N.; Liebler-Tenorio, E.M.; Grode, L.; Parzmair, G.; Krishnamoorthy, G.; Nieuwenhuizen, N.E.; Kaufmann, Stefan H. E.; Menge, C.

doi:10.3390/ijms24065509

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model

MPS-Authors

/persons/resource/persons248446

Kaufmann, Stefan H. E.
Emeritus Group Systems Immunology, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

ijms-24-05509.pdf
(出版社版), 5MB

付随資料 (公開)

There is no public supplementary material available

引用

Figl, J., Köhler, H., Wedlich, N., Liebler-Tenorio, E., Grode, L., Parzmair, G., Krishnamoorthy, G., Nieuwenhuizen, N., Kaufmann, S. H. E., & Menge, C. (2023). Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model. International Journal of Molecular Sciences, 24(6):. doi:10.3390/ijms24065509.

引用: https://hdl.handle.net/21.11116/0000-000C-F99E-A

要旨

A more effective vaccine against tuberculosis than Bacille Calmette-Guérin (BCG) is urgently needed. BCG derived recombinant VPM1002 has been found to be more efficacious and safer than the parental strain in mice models. Newer candidates, such as VPM1002 Δpdx1 (PDX) and VPM1002 ΔnuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did not affect the goats’ health in regards to clinical/hematological features. However, all three tested vaccine candidates and BCG induced granulomas at the site of injection, with some of the nodules developing ulcerations approximately one month post-vaccination. Viable vaccine strains were cultured from the injection site wounds in a few NUOG- and PDX- vaccinated animals. At necropsy (127 days post-vaccination), BCG, VPM1002, and NUOG, but not PDX, still persisted at the injection granulomas. All strains, apart from NUOG, induced granuloma formation only in the lymph nodes draining the injection site. In one animal, the administered BCG strain was recovered from the mediastinal lymph nodes. Interferon gamma (IFN-γ) release assay showed that VPM1002 and NUOG induced a strong antigen-specific response comparable to that elicited by BCG, while the response to PDX was delayed. Flow cytometry analysis of IFN-γ production by CD4⁺, CD8⁺, and γδ T cells showed that CD4⁺ T cells of VPM1002- and NUOG-vaccinated goats produced more IFN-γ compared to BCG-vaccinated and mock-treated animals. In summary, the subcutaneous application of VPM1002 and NUOG induced anti-tuberculous immunity, while exhibiting a comparable safety profile to BCG in goats.